@article{TAU12591,
author = {W. Robert Lee W. Robert Lee},
title = {Invited commentary on GETUG-AFU 16},
journal = {Translational Andrology and Urology},
volume = {5},
number = {6},
year = {2016},
keywords = {},
abstract = {I am grateful to accept the invitation to provide this commentary on the recently published article entitled “Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomized, multicenter, open-label phase 3 trial” (1). This important trial adds to the salvage radiotherapy literature which historically has been largely populated with retrospective analyses. The GETUG-AFU 16 trial observed improved progression-free survival when 6 months of goserelin was added to radiotherapy. In this short note I will provide a critical appraisal of the GETUG study, briefly describe another trial of salvage radiotherapy and androgen suppression (RTOG/NRG Oncology 96-01) and at the end describe how I incorporate the findings of each of these studies into my practice.},
issn = {2223-4691}, url = {https://tau.amegroups.org/article/view/12591}
}